FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject	STATEMENT
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b)	Filed no

OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CROCKER GARY L</u>					2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
					IN	INC [MACK]								X	Office	er (give title)	Other	(specify
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC. ONE BROADWAY 14TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/09/2022									See Remarks						
(Street)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
CAMBRIDGE MA 02142														Form filed by More than One Reporting Person					
(City)	(St	ate) (Ž	Zip)		1 03011														
		Table	I - N	lon-Deriva	tive	Secu	rities	Ac	quir	ed, D	isposed (of, or	Benefic	iall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye.				ear) i	2A. Deemed Execution Date if any (Month/Day/Ye		Date, Tran		action (Instr.				nd 5) Securit Benefic		ies Fo cially (D Following Ind		ct (I)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)	
Common Stock			06/09/202	22				P		4,452	A	\$5.1478	13		31,105		I	See footnote ⁽²⁾	
		Tal	ble I	I - Derivati (e.g., pu							posed of converti				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exed if an	Deemed cution Date, y nth/Day/Year)		Transaction of Code (Instr. Derivativ		rative rities ired r osed) r. 3, 4	Expiration Date (Month/Day/Year)			Amo Secu Undo Deriv Secu	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of erivative ccurity estr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	illy	10. Ownersh Form: Direct (D) or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Dat	te ercisable	Expiration Date	n Title	Number of Shares						

Explanation of Responses:

Remarks:

Chairman, President, and Treasurer

/s/ Gary L. Crocker 06/13/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.12 to \$5.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

^{2.} Shares held by Crocker Family Investments, LLC, over which Reporting Person is the Managing Member.